Pharma company challenges cancer treatment award

A Taiwanese pharmaceuticals company has challenged an award issued in a €2 billion ICC dispute over a blood cancer drug, arguing it was not allowed to defend itself against a claim raised later in the proceedings.


Get unlimited access to all Global Arbitration Review content